Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands
증권

Yahoo Finance

Viemed sees a sizable untapped home-ventilation market: Only about 60,000 beneficiaries currently receive its ventilation therapy, versus an estimated 1.25 million Medicare-eligible potential patients. The company serves more than 198,000 patients nationwide and focuses on complex respiratory conditions such as severe COPD.

Management expects low-20% revenue growth in 2026, projecting approximately $317 million in revenue and $66 million in EBITDA. Growth is supported by expanding sleep-resupply and maternal-health businesses, although these lower-margin segments may pressure EBITDA margins.

Viemed is prioritizing organic growth, strategic acquisitions and share repurchases while maintaining a debt-free balance sheet. The company has completed three acquisitions in three years and says leverage would remain below roughly two times EBITDA for any major deal.

MarketBeat previews the top five stocks to own by September 1st.

3 Undervalued Small-Cap Stocks for Your Labor Day Watchlist

Viemed Healthcare NASDAQ: VMD outlined its growth strategy, product diversification and capital allocation priorities at the Midwest IDEAS Conference, emphasizing its focus on providing in-home care for patients with complex respiratory conditions.

Chief Executive Officer Casey Hoyt said complex respiratory services account for roughly half of the company’s business. Viemed deploys respiratory therapists to care for patients at home, including those with chronic obstructive pulmonary disease, ALS and neuromuscular conditions that can cause respiratory failure. The company also provides sleep apnea products, oxygen therapy, airway-clearance devices, healthcare staffing and maternal health products.

Hoyt said Viemed serves patients in all 50 states and has more than 198,000 patients. He characterized the company’s primary opportunity as the underpenetrated market for home ventilation among patients with severe COPD. Of an estimated 25 million Americans with COPD, he said about 10% are in the most severe stage of the disease and roughly half of those may have chronic respiratory failure, making them potential candidates for ventilation therapy.

Home respiratory opportunity and technology

According to Hoyt, approximately 60,000 beneficiaries currently receive the company’s type of ventilation therapy, compared with an estimated 1.25 million Medicare-eligible patients who could qualify. He said Medicare penetration is about 5%, with overall penetration potentially near 10% after accounting for commercial payers.

For its ventilator business, Viemed receives about $1,050 per month on average for a machine on rent, Hoyt said. The rentals are uncapped, meaning the company can bill while the patient remains alive, and the average patient length of stay is about 17 months. Once equipment is returned, it can be cleaned, serviced and deployed to another patient.

The company has developed technology that connects respiratory equipment with a tablet used by respiratory therapists in patients’ homes. Hoyt said the system supports telehealth visits, captures therapy data, helps identify when a field visit may be needed and provides reporting for physicians and payers. He said the platform has also helped Viemed document patient compliance under a recently implemented National Coverage Determination governing qualification for ventilation therapy.

Hoyt cited three peer-reviewed studies funded by Viemed in 2021 and 2022. He said the studies found that the company’s care model reduced relative mortality by 43% and that early therapy utilization could save $5,400 per patient annually by reducing hospital and clinic visits.

While ventilation represented 47% of revenue in the company’s presentation, Viemed has been expanding other product categories. Hoyt said sleep therapy grew 44% in the prior year, while sleep resupply products—including masks, tubing and filters—grew 47% and account for 22% of overall revenue. Other cited revenue components included maternal health at 8%, oxygen at 8%, airway clearance at 7% and healthcare staffing at 7%.

The company has completed three acquisitions during the past three years. In June 2023, it acquired Home Medical Products, a Tennessee, northern Alabama and Mississippi provider that was primarily focused on sleep therapy. The transaction involved approximately $31 million of revenue, according to Hoyt.

Viemed also acquired a joint venture with East Alabama Medical Center in April 2024 in a transaction valued at $4.5 million. Hoyt said the operation is profitable and that the hospital has been pleased with its performance, though future joint ventures would need to be larger to justify the integration effort.

Its most recent acquisition, Lehan’s, added respiratory and maternal health capabilities. Hoyt described it as a roughly $28 million to $30 million transaction involving 100 employees. Lehan’s operated in Illinois before the acquisition, and Viemed has since expanded maternal health offerings into Texas and said Ohio is expected to come online, in addition to existing operations in Wisconsin, Illinois and parts of Indiana.

Financial outlook and capital deployment

Chief Operating Officer Todd Zehnder said Viemed expects revenue to grow in the low-20% range in 2026. Using the midpoint of full-year guidance, he cited projected revenue of $317 million and EBITDA of $66 million. The company reported trailing-12-month free cash flow of $34 million in its presentation and said net capital expenditures had declined to 8% of revenue, with full-year capital expenditure guidance of 9% to 10.5%.

Zehnder said the faster growth of sleep resupply and maternal health businesses is reducing capital intensity and supporting free cash flow, though those business lines also create some EBITDA-margin pressure because they have lower margins and do not generate depreciation and amortization associated with equipment purchases.

Management said Viemed has no net debt and has completed four share repurchase programs, including a current program under which it had repurchased just under 700,000 shares as of the second quarter. Zehnder said the company’s first capital-allocation priority remains organic growth, followed by acquisitions that fit its strategy. The company would use debt for a sufficiently large acquisition if warranted, he said, but does not expect leverage to exceed roughly two times EBITDA.

Addressing questions about sleep therapy, Zehnder said Viemed has not seen evidence that GLP-1 drugs or other treatments are reducing demand for CPAP products. Instead, he said the company has seen sleep business growth accelerate, potentially as more patients engage with physicians and receive sleep testing.

Viemed Healthcare, Inc NASDAQ: VMD is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Viemed Healthcare Right Now?

Before you consider Viemed Healthcare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viemed Healthcare wasn't on the list.

While Viemed Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports.

Check stock news, ratings, SEC filings, and more.

See daily stock ideas from top analysts.

Receive short-term trading ideas from MarketBeat.

Identify trending stocks on social media.

Advanced Stock Screeners and Research Tools

Use our seven stock screeners to find suitable stocks.

Stay informed with MarketBeat's real-time news.

Export data to Excel for personal analysis.

In-depth profiles and analysis for 20,000 public companies.

Real-time analyst ratings, insider transactions, earnings data, and more.

Our daily ratings and market update email newsletter.


출처 · Yahoo Finance

weeklynews 원문 보기

댓글

이 블로그 검색

나린 차이야싯, 놋빛 어둠 속에서 하나만 타는 히어로

AI 큐레이션 위클리뉴스 편집실 · Bangkok, 태국 초상만 놓고 보면 다른 작가의 것으로 착각하기 쉽다. 연보라 벽, 노란 메모지, 초록 화분, 그리고 웃음기가 남은 얼굴. 스무 명 가운데 가장 밝고 가장 편안한 방이다. 그런데 이 자리에서 만들어진 화면들은 하나같이 어둡고 묵직하다. 밝은 방에서 어두운 것을 만드는 사람의 초상이라고 해도 좋겠다. 그의 히어로 화면은 대부분 거의 검다. 그 위에 형상이 딱 하나 놓인다. 분홍 연꽃 한 송이, 주황으로 녹아내리는 능선, 등불이 걸린 산과 지붕. 이 형상들은 화면 가운데를 크게 차지하면서 안쪽에서 열을 내는 것처럼 보인다. 빛이 번지는 방향이 언제나 형상의 중심에서 바깥으로 향하기 때문이다. 움직임을 속도가 아니라 온도로 표현한 셈이다. 화면 밖에는 금속이 놓인다. 황동 주전자, 구리 받침, 옻빛 항아리, 은빛 화병. 이 사물들은 화면의 빛을 받아 자기 표면에서 한 번 더 굽힌다. 그래서 이미지 안에는 광원이 하나인데 반사는 여러 개다. 이 반복이 정지한 사진에 시간을 넣는다. 화면이 방금 켜졌는지 곧 꺼질지 알 수 없게 만드는 장치다. 색은 좁다. 주황, 구리, 자홍. 여기에 흰 카드가 아주 가끔 끼어들어 읽을 자리를 만든다. 흰 카드는 늘 형상 아래쪽이나 옆에 조심스럽게 붙고 결코 가운데를 침범하지 않는다. 정보가 형상에게 자리를 양보하는 이 순서가 스무 점 내내 지켜진다. 마지막에 이르면 열이 식는다. 같은 산과 지붕이 다시 등장하지만 이번에는 회갈색으로 가라앉았고, 방에는 금속 대신 초록 화분이 놓였다. 타오르던 것이 재가 되는 자리가 아니라, 불을 끄고 방의 조명을 켠 자리다. weeklynews 원문 보기

국경 밖 우리 국민의 창업 도전을 뒷받침한다

뉴스 중소벤처기업부 중소벤처기업부(장관 직무대행 제1차관 노용석, 이하 중기부)는 현지 시각 7월 24일(금), 스타트업·벤처 캠퍼스(SVC) 실리콘밸리에서 해외에서 활동하는 한인 창업가 간 교류를 촉진하고, 글로벌 창업 생태계와의 연결을 강화하기 위해 「K-파운더스 커넥트 인 실리콘밸리(K-Founders Connect in Silicon Valley)」를 개최한다고 밝혔다. < K-Founders Connect in Silicon Valley 개요 > ◦ (일시/장소) ‘26.7.24.(금) 13:30~15:00 (현지 시각) / 스타트업·벤처 캠퍼스 실리콘밸리 ◦ (참 석 자) 중기부 제1차관, 창업진흥원, KVIC, 스타트업, K-Founder 펀드 운용사, 재외국민, 현지 유학생, 한인 VC 등 70여 명 ◦ (주요내용) ’모두의 창업 글로벌 프로젝트‘ 계획 발표, K-Founder 펀드 출범식, 한인 선배 창업가의 진출 경험 공유, 질의응답 등 이번 행사는 노용석 중기부 제1차관을 비롯하여 스타트업, 재외국민, 유학생, 한인 VC, 창업지원기관 관계자 등 70여 명이 참석할 예정이다. 본 행사에서 「모두의 창업 글로벌 프로젝트」를 공식 발표하고 ‘K-Founder 펀드*’ 출범식을 함께 진행한다. 이후에는 링글의 이승훈 대표**가 예비창업가들을 대상으로 자신의 해외진출 경험을 공유한다. * (펀드명) ASQ Pioneer 펀드(운용사 : Valon Capital) ** 원어민 튜터 1:1 맞춤 화상영어 서비스를 제공하는 링글의 공동창업자로, 2019년부터 실리콘밸리에 해외지사를 설립해 활동중인 베테랑 창업가 1.「모두의 창업 글로벌 프로젝트」발표 「모두의 창업 글로벌 프로젝트」는 창업 지원 대상을 재외국민과 유학생까지 확대하여 해외에서도 우리 국민이 글로벌 창업에 도전할 수 있도록 지원하는 사업이다. 이 사업은 지난 3월 싱가포르에서 열린 ‘AI 커넥트 서밋(Connect Summit)’에서 한 유학생이 "해외에 있는 우리 청년들...

미국 프랜차이즈 시장 진출 전략 프로그램 US BUSINESS INSIGHTS 2026 참가기업 모집 공고

정부지원사업 산업통상부 · 마감 2026-10-30 소관부처·지자체 산업통상부 사업수행기관 한국프랜차이즈산업협회 신청기간 2026.10.16 ~ 2026.10.30 사업개요 한국프랜차이즈산업협회 미국지회(KFA USA)에서 미국 시장 진출 및 현지 사업 확장을 희망하는 기업을 대상으로 「US BUSINESS INSIGHTS 2026」 참가기업을 모집합니다. 본 프로그램은 미국 캘리포니아주 로스앤젤레스(LA)와 오렌지카운티의 주요 상권ㆍ매장 탐방, 분야별 전문가 세미나, 브랜드 피칭 및 현지 파트너ㆍ투자자와의 비즈니스 상담으로 구성됩니다. 미국 시장에 대한 이해를 높이고, 자사 브랜드에 적합한 진출 방향과 현지 협력 가능성을 검토하고자 하는 회원사 여러분의 많은 관심과 참여 바랍니다. ☞ 미국 진출 및 사업 확장을 희망하는 프랜차이즈 기업ㆍ브랜드 등 ☞ 현지 상권ㆍ매장 탐방, 미국 진출 실무 세미나, 브랜드 피칭ㆍIR 및 비즈니스 상담, 현지 네트워킹 지원 ※ 자세한 지원내용 공고문 참조 사업신청 방법 이메일 접수 (services@kfausa.net) ※ 자세한 신청방법 공고문 참조 문의처 한국프랜차이즈산업협회 미국지회(KFA USA) +1-562-246-6715, services@kfausa.net / 카카오톡ID kfausa ※ 본 지원사업에 대한 문의˙신청 등의 모든 절차는 수행기관에서 전담하고 있음을 안내드립니다. 출처 · 기업마당 weeklynews 원문 보기